For the year ending 2025-12-31.
| Income Statement | 2025-12-31 | 2024-12-31 | ||
|---|---|---|---|---|
| Research and development | 66,267 | 51,964 | ||
| General and administrative | 16,984 | 18,613 | ||
| Total operating expenses | 83,251 | 70,577 | ||
| Other income, net | 4,220 | 3,924 | ||
| Change in fair value of warrant liabilities and fair value of financial instruments issued in excess of proceeds | - | -30,900 | ||
| Change in fair value of warrant liabilities | -33,449 | - | ||
| Loss before income taxes | -45,582 | -35,753 | ||
| Provision for income taxes | 35 | 431 | ||
| Net loss | -45,617 | -36,184 | ||
| Basic EPS | -0.52 | - | ||
| Diluted EPS | -0.52 | - | ||
| Basic Average Shares | 81,836,246 | - | ||
| Diluted Average Shares | 81,836,246 | - | ||
Eledon Pharmaceuticals, Inc. (ELDN)
Eledon Pharmaceuticals, Inc. (ELDN)